surmount-1 tirzepatide weight loss percent nejm 2022 SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes Tirzepatide and Semaglutide key differences,

Consistent weekly timing matters more than any single missed injection over the course of treatment

The SURMOUNT-5 trial published in the New England Journal of Medicine in May 2025 was the first randomized, head-to-head comparison of the two medications in patients with obesity but without type 2 diabetes

You shouldnt use heat to warm the drug before injecting it, but you can take Zepbound out of the fridge and let it warm to room temperature prior to injecting if that makes administration more comfortable for you

November 2025: FDA approved expanded Zepbound (tirzepatide) indication for moderate-to-severe obstructive sleep apnea in adults with obesity, following SURMOUNT-OSA trial data showing 62.8% reduction in apnea-hypopnea index the first drug approval for sleep apnea treatment

* The 30-Gram Rule: Aim for at least 30 grams of protein at every meal

Myth #5: Its Complicated to Take or Hard to Tolerate Fact: Tirzepatide (Mounjaro/Zepbound) is administered as a once-weekly injection, making it simple and convenient